Drugs / lometrexol
lometrexol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00024310 | Sep 2001 → ? | poisoning | Jonsson Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00033722 | Feb 2002 → ? | lung cancer | Tularik | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lometrexol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00033722 ↗ |
| Known as | LOMETREXOL SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL34412 ↗ |
| Known as | LY-264618 DISODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL34412 ↗ |
| Known as | LY264618 | ChEMBL registry synonym — accepted as the source's own label CHEMBL34412 ↗ |
| Known as | NSC-722969 | ChEMBL registry synonym — accepted as the source's own label CHEMBL34412 ↗ |
| Action | Inhibit | “Lometrexol may stop the growth of tumors by blocking one of the enzymes necessary for cancer cell growth.” NCT00024310 ↗ |
| Modality | Small molecule | — CHEMBL34412 ↗ |
| Route | Intravenous | “Patients receive lometrexol IV over 30-60 seconds immediately followed by paclitaxel IV over 3 hours on day 1.” NCT00024310 ↗ |